Investors are closely watching the beverage giant's Q3 results on Monday for insights into the health of the alcoholic beverage market.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
State tech hub funding and an expanded partnership with Ember Recreational Vehicles fuel investor optimism in the battery manufacturer.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.
A potential leadership reshuffle at the tech giant reportedly positions hardware engineering chief John Ternus to eventually succeed Tim Cook.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
The pharmaceutical giant is now considered one of Morningstar's highest-conviction undervalued stocks, citing a robust pipeline and strategic acquisitions.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.